The effects of a subpsychotic dose of ketamine on recognition and source memory for agency: Implications for pharmacological modelling of core symptoms of schizophrenia

Neuropsychopharmacology

Volumn 31, Issue 2, 2006, Pages 413-423

  Honey, Garry D ^a   O'Loughlin, Chris ^a   Turner, Danielle C ^a   Pomarol Clotet, Edith ^a   Corlett, Philip R ^a   Fletcher, Paul C ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Ketamine; Multinomial modelling; NMDA; Schizophrenia; Source memory

Indexed keywords

KETAMINE; PLACEBO;

ADULT; ARTICLE; ASSOCIATION; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELUSIONAL DISORDER; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INFUSION; HUMAN; HUMAN EXPERIMENT; LONG TERM MEMORY; MALE; MEMORY CONSOLIDATION; MENTAL DISEASE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECALL; RECOGNITION; SCHIZOPHRENIA; TASK PERFORMANCE; WORD RECOGNITION;

ADOLESCENT; ADULT; DOUBLE-BLIND METHOD; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; KETAMINE; MALE; MEMORY DISORDERS; MENTAL RECALL; MODELS, PSYCHOLOGICAL; NEUROPSYCHOLOGICAL TESTS; RECOGNITION (PSYCHOLOGY); SCHIZOPHRENIC PSYCHOLOGY; VERBAL LEARNING;

EID: 30944451560     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1300846     Document Type: Article

References (59)

1. Abel KM, Allin MP, Hemsley DR, Geyer MA (2003). Low dose ketamine increases prepulse inhibition in healthy men. Neuropharmacology 44: 729-737.
2. Batchelder WH, Chosak-Reiter J, Shankle WR, Dick MB (1997). A multinomial modeling analysis of memory deficits in Alzheimer's disease and vascular dementia. J Gerontol B Psychol Sci Soc Sci 52: 206-215.
3. Batchelder WH, Riefer DM (1990). Multinomial processing models of source monitoring. Psychol Rev 97: 548-564.
4. Bayen UJ, Murnane K, Erdfelder E (1996). Source discrimination, item detection, and multinomial models of source monitoring. J Exp Psychol-Learning Memory Cognition 22: 197-215.
5. Bentall R, Slade P (1985). Reality testing and auditory hallucinations: a signal detection hypothesis. Br J Clin Psychol 24: 159-169.
6. Bentall RP, Baker GA, Havers S (1991). Reality monitoring and psychotic hallucinations. Br J Clin Psychol 30: 213-222.
7. Bowdle TA, Radant AD, Cowley DS, Kharasch ED, Strassman RJ, Roy-Byrne PP (1998). Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations. Anesthesiology 88: 82-88.
8. Brebion G, Amador X, David A, Malaspina D, Sharif Z, Gorman JM (2000). Positive symptomatology and source-monitoring failure in schizophrenia - an analysis of symptom-specific effects. Psychiatr Res 95: 119-131.
9. Brebion G, Amador X, Smith MJ, Malaspina D, Sharif Z, Gorman JM (1999). Opposite links of positive and negative symptomatology with memory errors in schizophrenia. Psychiatr Res 88: 15-24.
10. Brebion G, Gorman JM, Amador X, Malaspina D, Sharif Z (2002). Source monitoring impairments in schizophrenia: characterisation and associations with positive and negative symptomatology. Psychiatr Res 112: 27-39.
11. Brebion G, Smith MJ, Gorman JM, Amador X (1996). Reality monitoring failure in schizophrenia: the role of selective attention. Schizophr Res 22: 173-180.
12. Brebion G, Smith MJ, Gorman JM, Amador X (1997). Discrimination accuracy and decision biases in different types of reality monitoring in schizophrenia. J Nerv Ment Dis 185: 247-253.
13. Craik FIM, Lockhart RS (1972). Levels of processing: a framework for memory research. J Verbal Learning Verbal Behav 11: 671-684.
14. Danion JM, Rizzo L, Bruant A (1999). Functional mechanisms underlying impaired recognition memory and conscious awareness in patients with schizophrenia. Arch Gen Psychiatr 56: 639-644.
15. Dodson CS, Prinzmetal W, Shimamura AP (1998). Using Excel to estimate parameters from observed data: an example from source memory data. Behav Res Methods Instrum Comput 30: 517-526.
16. Domino EF, Zsigmond EK, Domino LE, Domino KE, Kothary SP, Domino SE (1982). Plasma levels of ketamine and two of its metabolites in surgical patients using a gas chromatographic mass fragmentographic assay. Anesth Analg 61: 87-92.
17. Duncan EJ, Madonick SH, Parwani A, Angrist B, Rajan R, Chakravorty S et al (2001). Clinical and sensorimotor gating effects of ketamine in normals. Neuropsychopharmacology 25: 72-83.
18. Francis WN, Kucera H (1982). Frequency Analysis of English Usage: Lexicon and Grammar. Houghton Mifflin: Boston.
19. Frith C (1992). The Cognitive Neuropsychology of Schizophrenia. Lawrence Erlbaum: Hove.
20. Frith CD (1987). The positive and negative symptoms of schizophrenia reflect impairments in the perception and initiation of action. Psychol Med 17: 631-648.
21. Frith CD, Done DJ (1989). Experiences of alien control in schizophrenia reflect a disorder in the central monitoring of action. Psychol Med 19: 359-363.
22. Ghoneim MM, Hinrichs JV, Mewaldt SP, Petersen RC (1985). Ketamine: behavioral effects of subanesthetic doses. J Clin Psychopharmacol 5: 70-77.
23. Harris JA, Biersner RJ, Edwards D, Bailey LW (1975). Attention, learning, and personality during ketamine emergence: a pilot study. Anesth Analg 54: 169-172.
24. Harvey PD (1985). Reality monitoring in mania and schizophrenia. The association of thought disorder and performance. J Nerv Ment Dis 173: 67-73.
25. Hetem LA, Danion JM, Diemunsch P, Brandt C (2000). Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (Berlin) 152: 283-288.
26. Honey GD, Honey RA, O'Loughlin C, Sharar SR, Kumaran D, Suckling J et al (2005). Ketamine disrupts frontal and hippocampal contribution to encoding and retrieval of episodic memory: an FMRI study. Cereb Cortex 15: 749-759.
27. Honey GD, Honey RAE, Sharar SR, Turner DC, Pomarol-Clotet E, Kumaran D et al (in press). Impairment of specific episodic memory processes by sub-psychotic doses of ketamine: the effects of levels of processing at encoding and of the subsequent retrieval task. Psychopharmacology.
28. Honey RA, Honey GD, O'Loughlin C, Sharar SR, Kumaran D, Bullmore ET et al (2004). Acute ketamine administration alters the brain responses to executive demands in a verbal working memory task: an FMRI study. Neuropsychopharmacology 29: 1203-1214.
29. Honey RA, Turner DC, Honey GD, Sharar SR, Kumaran D, Pomarol-Clotet E et al (2003). Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory. Neuropsychopharmacology 30: 30.
30. Johnson MK, Raye CL (1981). Reality monitoring. Psychol Rev 88: 67-85.
31. Keefe RS, Poe MP, McEvoy JP, Vaughan A (2003). Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. Psychopharmacology (Berlin) 169: 383-389.
32. Keefe RSE (1998). The neurobiology of disturbances of the self: autonoetic agnosia in schizophrenia. In: Amador XF, David A (eds). Insight and Psychosis. Oxford University Press: New York.
33. Keefe RSE, Arnold MC, Bayen UJ, Harvey PD (1999). Source monitoring deficits in patients with schizophrenia; a multinomial modelling analysis. Psychol Med 29: 903-914.
34. Keefe RSE, Arnold MC, Bayen UJ, McEvoy JP, Wilson WH (2002). Source-monitoring deficits for self-generated stimuli in schizophrenia: multinomial modeling of data from three sources. Schizophr Res 57: 51-67.
35. Krystal JH, Karper LP, Bennett A, D'Souza DC, Abi-Dargham A, Morrissey K et al (1998). Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans. Psychopharmacology (Berlin) 135: 213-229.
36. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994). Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatr 51: 199-214.
37. Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001). Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455-467.
38. Laroi F, Van der Linden M, Marczewski P (2004). The effects of emotional salience, cognitive effort and meta-cognitive beliefs on a reality monitoring task in hallucination-prone subjects. Br J Clin Psychol 43(Part 3): 221-233.
39. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D et al (1997). Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 17: 141-150.
40. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D et al (1996). NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology 14: 301-307.
41. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004a). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29: 208-218.
42. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004b). Ketamine impairs response inhibition and is positively reinforcing in healthy volunteers: a dose-response study. Psychopharmacology 15: 15.
43. Moritz S, Woodward TS, Ruff CC (2003). Source monitoring and memory confidence in schizophrenia. Psychol Med 33: 131-139.
44. Morrison AP, Haddock G (1997). Cognitive factors in source monitoring and auditory hallucinations. Psychol Med 27: 669-679.
45. Nelson H (1982). National Adult Reading Test. NFER-Nelson Publishing Company Ltd: New York.
46. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T et al (1999). Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology 20: 106-118.
47. Olney JW, Farber NB (1995). Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatr 52: 998-1007.
48. Passie T, Karst M, Borsutzky M, Wiese B, Emrich HM, Scneider U (2003). Effects of different subanaesthetic doses of (S)-ketamine on psychopathology and binoculr depth inversion in man. J Psychopharmacol 17: 51-56.
49. Passie T, Karst M, Wiese B, Emrich HM, Schneider U (2005). Effects of different subanaesthetic doses of (S)-ketamine on Neuropsychology, Psychopathology and State of Conciousness in Man. Neuropsychobiology 51: 226-233.
50. Radant AD, Bowdle TA, Cowley DS, Kharasch ED, Roy-Byrne PP (1998). Does ketamine-mediated N-methyl-D-aspartate receptor antagonism cause schizophrenia-like oculomotor abnormalities? Neuropsychopharmacology 19: 434-444.
51. Rankin PM, O'Carroll PJ (1995). Reality discrimination, reality monitoring and disposition towards hallucination. Br J Clin Psychol 34(Part 4): 517-528.
52. Riefer DM, Batchelder WH (1988). Multinomial modeling and the measurement of cognitive-processes. Psychol Rev 95: 318-339.
53. Simons JS, Verfaellie M, Galton CJ, Miller BL, Hodges JR, Graham KS (2002). Recollection-based memory in frontotemporal dementia: implications for theories of long-term memory. Brain 125: 2523-2536.
54. Slamecka NJ, Graf P (1978). The generation effect: delineation of a phenomenon. J Exp Psychol: Hum Learning Memory 4: 592-604.
55. Stirling JD, Hellewell JS, Hewitt J (1997). Verbal memory impairment in schizophrenia: no sparing of short-term recall. Schizophr Res 25: 85-95.
56. Tamminga CA, Holcomb HH, Gao XM, Lahti AC (1995). Glutamate pharmacology and the treatment of schizophrenia: current status and future directions. Int Clin Psychopharmacol 10(Suppl 3): 29-37.
57. Vinogradov S, Willis-Shore J, Poole JH, Marten E, Ober BA, Shenaut GK (1997). Clinical and neurocognitive aspects of source monitoring errors in schizophrenia. Am J Psychiatr 154: 1530-1537.
58. Vollenweider FX, Leenders KL, Scharfetter C, Maguire P, Stadelmann O, Angst J (1997). Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis. Neuropsychopharmacology 16: 357-372.
59. Wing J, Cooper J, Sartorius N (1974). The Measurement and Classification of Psychiatric Symptoms. Cambridge Universtiy Press: Cambridge.